



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Date: 14th August, 2018

To,
National Stock Exchange of India Limited,
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai- 400051

Sub: - Outcome of Board Meeting held on 14th August, 2018

Dear Sir/Madam,

A meeting of the Board of Directors of the company was held on Tuesday, the 14th day of August, 2018 at 11:30 a.m. at the Corporate Office of the Company and concluded at 4.20 p. m. The Board *inter-alia* considered and approved the Unaudited Financial Results (both Standalone and Consolidated) of the company for the first quarter of the financial year 2018-19 ended on 30th June, 2018.

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith, the Unaudited Financial Results (Standalone and Consolidated basis) as on 30th June, 2018 of the Company along with the Limited Review Report given by the Statutory Auditors of the Company on the Unaudited Financial Results for the quarter ended on 30th June, 2018.

Further, pursuant to Regulation 42 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the register of members and share transfer books will be closed from 23rd September, 2018 to 29th September, 2018 (both days inclusive).

Further, the 34th Annual General Meeting of the company will be held on Saturday, the 29th day of September, 2018, at 9.30 a.m. at the Classique Club, Behind Infinity Mall, Link Road, Oshiwara, Andheri (West), Mumbai-400 053.

This is for the information of the exchange and members thereof.

You are requested to take the same on record.

Thanking You

For Parenteral Drugs (India) Limited

Company Secretary

Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481





PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

PARENTERAL DRUGS (INDIA) LIMITED
Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE 1 ST QUARTER ENDED ON 30TH JUNE . 2018

Sr. No.	Particulars	(Rs in Lakh, unless otherwise stated)			
		Quarter Ended 30-06-2018 (Un-Audited)	Quarter Ended 31-03-2018 (Audited)	Quarter Ended 30-06-2017 (Un-Audited)	Year Ended 31-03-2018 (Audited)
	Income				
I	(a) Revenue From Operation (Net of excise duty)	1,056.32	513.46	1,111.11	3,297.13
II	(b) Other Operating Income	2.41	17.33	63.69	134.41
III	Total Income (I+II)	1,058.73	530.79	1,174.80	3,431.54
IV	Expenditure				
	Cost of Material Consumed	196.18	85.90	107.45	439.20
	Purchase of Stock In Trade	-	23.63	84.67	131.15
	Change in Inventories of Finished Goods, Stock In trade and Work in Progress	(46.79)	(22.10)	23.06	105.82
	Employee Benefit Expenses	497.83	478.98	324.07	1,669.69
	Finance costs	2,285.46	2,220.04	2,021.43	8,634.00
	Depreciation, Amortisation and Impairment Expenses	464.89	499.47	452.68	1,856.65
	Other Expenditure	637.44	491.16	856.93	2,535.30
	Total Expenses (IV)	4,035.01	3,777.09	3,870.29	15,371.81
V	Profit / (Loss) before exceptional items and Tax (I-IV)	(2,976.28)	(3,246.30)	(2,695.49)	(11,940.27)
VI	Exceptional items	-	-	-	-
VII	Profit / (Loss) before Tax (V-VI)	(2,976.28)	(3,246.30)	(2,695.49)	(11,940.27)
VIII	Tax Expenses				
	(1) Current Tax	-	-	-	-
	(2) Deferred Tax	(592.25)	(516.88)	(554.31)	(2,331.05)
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(2,384.03)	(2,729.42)	(2,141.18)	(9,609.22)
X	Net Profit / (Loss) for the period from discontinuing operations	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-
XII	Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	(2,384.03)	(2,729.42)	(2,141.18)	(9,609.22)
XIV	Other Comprehensive Income				
	A (i) Item that will not be reclassified to Profit or loss	(1.09)	61.23	(0.44)	(2.31)
	(ii) Income tax relation to Item that will not be reclassified to Profit or loss	-	-	-	-
	B (i) Item that will be reclassified to Profit or loss	-	-	-	-
	(ii) Income tax relation to Item that will be reclassified to Profit or loss	-	-	-	-
XV	Total comprehensive Income for the period (XIII+XIV) (comprising profit (loss) and other comprehensive income for the period)	(2,385.12)	(2,668.19)	(2,141.62)	(9,611.53)
XVI	Paid Up Equity share capital (Face value Rs.10/-each)	2,981.63	2,981.63	2,981.63	2,981.63
XVII	Earnings per share (for continuing operation) :				
	(a) Basic (In Rs)	(8.00)	(9.15)	(7.18)	(32.23)
	(b) Diluted (In Rs)	(8.00)	(9.15)	(7.18)	(32.23)
XVIII	Earnings per share (for discontinued operation) :				
	(a) Basic (In Rs)	-	-	-	-
	(b) Diluted (In Rs)	-	-	-	-
XIX	Earnings per share (for discontinued & continuing operation) :				
	(a) Basic (In Rs)	(8.00)	(9.15)	(7.18)	(32.23)
	(b) Diluted (In Rs)	(8.00)	(9.15)	(7.18)	(32.23)

Notes to the financial results:

- The above results were reviewed by statutory auditors and audit committee of the company held on 13-08-2018 and approved by Board of Directors in their meeting held on 14-08-2018.
- The above standalone financial results for the quarter ended 30 th June 2018 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017, the Company has for the first time adopted Ind AS with the transition date of April 1, 2016.
- The Government of India introduced the GST with effect from 1 st July 17 which subsumes excise duty and various indirect taxes. As required under Ind AS 18, revenue for the quarter ended 30th June 2018 are reported net of GST and hence previous corresponding quarter ended on 30 th June 2017 are not comparable.
- At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.
- The figures for the quarter ended March 31, 2018 are the balancing figures between audited figures in respect of the full financial year and the unaudited published figures upto nine months of the financial year.
- The previous period figures have been regrouped/rearranged wherever found necessary.
- The Standalone financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

For & on behalf of the Board of Directors

Place: Indore

Date: 14-08-2018

Vinod Kumar Gupta
Managing Director
DIN 00039145



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M5080912HF

JAS-ANZ



www.jas-anz.org/register



Standalone Limited Review Report

Limited Review Report to

The Board of Directors of Parenteral Drugs (India) Limited

We have reviewed the accompanying statement of unaudited financial results of **Parenteral Drugs (India) Limited** for the quarter ended **30th June, 2018** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent auditor of the entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. IND AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore

Date: 14-08-2018

For Singhal Jain & Co.

Chartered Accountants



Kamal Jain
CA Kamal Jain
(Partner)

M. No. 406604

F.R.N.013995C



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

UN AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE I ST QUARTER ENDED ON 30TH JUNE, 2018

Sr. No.	Particulars	(Rs in Lakh, unless otherwise stated)			
		Quarter Ended 30-06-2018 (Un Audited)	Quarter Ended 31-03-2018 (Audited)	Quarter Ended 30-06-2017 (Un Audited)	Year Ended 31-03-2018 (Audited)
I	(a): Revenue From Operation(Net of excise duty)	4908.06	4630.24	6,244.18	21711.04
II	(b): Other Income	16.74	31.32	71.29	159.27
III	Total Income (I+II)	4924.80	4661.56	6,315.47	21870.31
IV	Expenditure				
	Cost of Material Consumed	2872.79	10.90	2,351.71	7125.99
	Purchase of Stock In Trade	192.62	1686.83	2,355.79	6655.52
	Change in Inventories of Finished Goods, Stock In trade and Work in Progress	-764.25	574.96	175.80	1860.45
	Employee Benefit Expenses	678.55	623.23	440.98	2193.49
	Finance costs	2555.07	2484.50	2,307.80	9754.26
	Depreciation and Amortisation Expenses	606.84	618.57	602.40	2424.33
	Other Expenditure	1815.22	1251.47	1,785.39	5981.24
	Total Expenses (IV)	7956.84	7250.47	10019.87	35995.28
V	Profit / (Loss) before exceptional items and Tax (I-IV)	(3,032.04)	(2,588.91)	(3,704.40)	(14,124.97)
VI	Exceptional items				
VII	Profit / (Loss) before Tax (V-VI)	(3,032.04)	(2,588.91)	(3,704.40)	(14,124.97)
VIII	Tax Expenses				
	(1) Current Tax	-	-	-	-
	(2) Deferred Tax	(574.19)	(478.72)	(527.24)	(2230.77)
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(2,457.85)	(2,110.20)	(3,177.16)	(11,894.20)
X	Net Profit / (Loss) for the period from discontinuing operations	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-
XII	Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	(2,457.85)	(2,110.20)	(3,177.16)	(11,894.20)
XIV	Other Comprehensive Income				
	A (i) Item that will not be reclassified to Profit or loss	(0.36)	58.46	(0.44)	(5.08)
	(ii) Income tax relation to Item that will not be reclassified	-	-	-	-
	B (i) Item that will be reclassified to Profit or loss	-	-	-	-
	(ii) Income tax relation to Item that will be reclassified to Profit or loss	-	-	-	-
XV	Total comprehensive Income for the period (XIII+XIV)(comprising profit (loss) and other comprehensive income for the period)	(2,458.21)	(2,051.74)	(3,177.60)	(11,899.28)
XVI	Paid Up Equity share capital(Face value Rs.10/-each)	2,981.63	2,981.63	2,981.63	2,981.63
XVII	Earnings per share (for continuing operation) :				
	(a) Basic	(8.24)	(7.08)	(10.66)	(39.89)
	(b) Diluted	(8.24)	(7.08)	(10.66)	(39.89)
XVIII	Earnings per share (for discontinued operation) :				
	(a) Basic	-	-	-	-
	(b) Diluted	-	-	-	-
XIX	Earnings per share (for discontinued & continuing operation) :				
	(a) Basic	(8.24)	(7.08)	(10.66)	(39.89)
	(b) Diluted	(8.24)	(7.08)	(10.66)	(39.89)



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F

JAS-ANZ



www.jas-anz.org/register



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Notes to the financial results:

- 1 The above results were reviewed by statutory auditors and audit committee of the company held on 13-08-2018 and approved by Board of Directors in their meeting held on 14-08-2018.
- 2 Additional information on standalone financial results are given below:

Particulars	Rs. In Lakh			
	Quarter Ended 30-06-2018 (Un Audited)	Quarter Ended 31-03-2018 (Audited)	Quarter Ended 30-06-2017 (Un Audited)	Year to Ended 31-03-2018 (Audited)
Total Income from operations	1,058.73	530.79	1,174.80	3,431.54
Profit/Loss before tax	(2,976.28)	(3,246.30)	(2,695.49)	(11,940.27)
Profit/Loss after tax	(2,385.12)	(2,668.19)	(2,141.62)	(9,611.53)

The above consolidated financial results for the quarter ended 30th June, 2018 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017, the Company has for the first time adopted Ind AS with the transition date of April 1, 2016

- 4 The Government of India introduced the GST with effect from 1st July 17 which subsumes excise duty and various indirect taxes. As required under Ind AS 18, revenue for the quarter ended 30th June 2018 are reported net of GST and hence previous corresponding quarter ended on 30th June 2017 are not comparable.
- 5 At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.
- 6 The figures for the quarter ended March 31, 2018 are the balancing figures between audited figures in respect of the full financial year and the unaudited published figures upto nine months of the financial year.
- 7 The previous period figures have been regrouped/rearranged wherever found necessary.
- 8 The Consolidated financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

For & on behalf of the Board of Directors

Place: Indore
Date: 14-08-2018



Vinod Kumar Gupta
Managing Director
DIN 00039145

Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481



DRS is Accredited by
JAS-ANZ M50809121F



www.jas-anz.org/register

Consolidated Limited Review Report

Limited Review Report to

The Board of Directors of Parenteral Drugs (India) Limited

We have reviewed the accompanying statement of unaudited financial results of **Parenteral Drugs (India) Limited** and its subsidiaries for the quarter ended **30th June, 2018** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent auditor of the entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The financial results and other financial information of the subsidiaries have not been subjected to review and have been presented based on the financial information compiled by the company.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. IND AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore

Date: 14-08-2018

For Singhal Jain & Co.

Chartered Accountants



Kamal Jain
CA Kamal Jain
(Partner)

M. No. 406604

F.R.N.013995C